Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061659 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma
A Phase 2 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT00061659 is a Phase 2 study that has completed, run by Abbott. The registered enrollment target is 88 participants.
The verdict
NCT00061659, a Phase 2 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with locally advanced or metastatic soft tissue sarcoma.
Interventions
- DRUG ABT-510 - Thrombospondin-1 mimetic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2003-05 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00061659
The ClinicalTrials.gov registry entry for NCT00061659 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABT-510 - Thrombospondin-1 mimetic is the first listed.
NCT00061659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00061659 about?
NCT00061659 is a clinical study titled "Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma". The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with locally advanced or metastatic soft tissue sarcoma.
What is the current status of trial NCT00061659?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2003-05. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00061659?
The interventions under investigation include: ABT-510 - Thrombospondin-1 mimetic (DRUG).
Who is sponsoring clinical trial NCT00061659?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.